Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: A systematic review and meta-analysis

Journal of Clinical Psychiatry

Volumn 69, Issue 10, 2008, Pages 1589-1601

  Bond, David J ^a   Noronha, Melissa M ^a   Kauer Sant'Anna, Marcia ^a   Lam, Raymond W ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLORGYLINE; ESCITALOPRAM; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OXAZEPAM; PARGYLINE; PAROXETINE; PHENELZINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZOPICLONE;

ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MOOD CHANGE; MOOD DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 54949113645     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1009     Document Type: Article

References (44)

1. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269
2. Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-535
3. Manning JS, Haykal RF, Connor PD, et al. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997;38:102-108
4. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998;50:163-173
5. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 2007 Jan;58(1):85-91
6. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7(suppl 3):5-69
7. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005 July;66(7):870-886
8. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(supp 4):1-50
9. McMahon FJ, Simpson SG, McInnis MG, et al. Linkage of bipolar disorder to chromosome 18q and the validity of bipolar II disorder. Arch Gen Psychiatry 2001;58:1025-1031
10. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976;11:31-42
11. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999;14:277-281
12. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14:283-285
13. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
14. Coryell W, Endicott J, Maser JD, et al. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-390
15. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6:32-42
16. Visser HM, Van Der Mast RC. Bipolar disorder, antidepressants and induction of hypomania or mania: a systematic review. World J Biol Psychiatry 2005;6:231-241
17. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-213
18. Normann C, Hummel B, Schärer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002 Apr;63(4):337-344
19. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007 May;115(5):360-365
20. Pickar D, Murphy DL, Cohen RM, et al. Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry 1982;39:535-540
21. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-916
22. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997;46:73-77
23. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001 Apr;62(4):249-255
24. Joffe RT, MacQueen GM, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002;105:427-430
25. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002 Jun;63(6):508-512
26. Fonseca M, Soares JC, Hatch JP, et al. An open trial of adjunctive escitalopram in bipolar depression. J Clin Psychiatry 2006 Jan;67(1):81-86
27. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-239
28. Schaffer A, Zuker P, Levitt A, et al. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-99
29. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722
30. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006;163:313-315
31. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-216
32. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-126
33. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:414-417
34. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065-1069
35. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003 Apr;64(4):403-407
36. Amsterdam JD, Garcia-España F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-440
37. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-433
38. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000 Nov;61(11):841-850
39. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609
40. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
41. Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder? a proof of concept study. J Affect Disord 2006 Jun;92(2-3):205-214
42. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003;54:9-16
43. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychpharmacol 2008 Apr;28(2):171-181
44. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547